riluzole has been researched along with Autosomal Dominant Cerebellar Ataxia, Type II in 8 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole has been reported to be beneficial in patients with cerebellar ataxia; however, effectiveness in individual subtypes of disease is unclear due to heterogeneity in participants' causes and stages of disease." | 3.11 | Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. ( Anheim, M; Brice, A; Calvas, F; Calvas, P; Chupin, M; Coarelli, G; Devos, D; Durr, A; Ewenczyk, C; Fischer, C; Goizet, C; Heinzmann, A; Hurmic, H; Mangin, JF; Monin, ML; Nguyen, K; Ricigliano, VAG; Tezenas du Montcel, S; Thobois, S; Verny, C, 2022) |
| "Patients with spinocerebellar ataxia or Friedreich's ataxia (2:1 ratio) from three Italian neurogenetic units were enrolled in this multicentre, double-blind, placebo-controlled trial, and randomly assigned to riluzole (50 mg orally, twice daily) or placebo for 12 months." | 2.80 | Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. ( Casali, C; Coarelli, G; Ferraldeschi, M; Frontali, M; Leonardi, L; Marcotulli, C; Orzi, F; Petrucci, A; Piccolo, F; Ponzelli, F; Ristori, G; Romano, S; Salvetti, M; Spadaro, M; Vanacore, N; Vulpiani, MC, 2015) |
| "Spinocerebellar ataxias are autosomal dominant diseases, associated in some types with a CAG repeat expansion, and characterised by a progressive loss of motor function." | 1.39 | Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. ( Nag, N; Storey, E; Tarlac, V, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coarelli, G | 2 |
| Heinzmann, A | 1 |
| Ewenczyk, C | 1 |
| Fischer, C | 1 |
| Chupin, M | 1 |
| Monin, ML | 1 |
| Hurmic, H | 1 |
| Calvas, F | 1 |
| Calvas, P | 1 |
| Goizet, C | 1 |
| Thobois, S | 1 |
| Anheim, M | 1 |
| Nguyen, K | 1 |
| Devos, D | 1 |
| Verny, C | 1 |
| Ricigliano, VAG | 1 |
| Mangin, JF | 1 |
| Brice, A | 1 |
| Tezenas du Montcel, S | 1 |
| Durr, A | 2 |
| Velázquez-Pérez, L | 1 |
| Rodríguez-Labrada, R | 1 |
| Klockgether, T | 1 |
| Mariotti, C | 1 |
| Paulson, HL | 1 |
| Romano, S | 1 |
| Marcotulli, C | 1 |
| Leonardi, L | 1 |
| Piccolo, F | 1 |
| Spadaro, M | 1 |
| Frontali, M | 1 |
| Ferraldeschi, M | 1 |
| Vulpiani, MC | 1 |
| Ponzelli, F | 1 |
| Salvetti, M | 1 |
| Orzi, F | 1 |
| Petrucci, A | 1 |
| Vanacore, N | 1 |
| Casali, C | 1 |
| Ristori, G | 1 |
| Wood, H | 1 |
| Ishida, Y | 1 |
| Kawakami, H | 1 |
| Kitajima, H | 1 |
| Nishiyama, A | 1 |
| Sasai, Y | 1 |
| Inoue, H | 1 |
| Muguruma, K | 1 |
| Nag, N | 1 |
| Tarlac, V | 1 |
| Storey, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2[NCT03347344] | Phase 3 | 42 participants (Actual) | Interventional | 2018-01-17 | Completed | ||
| Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial.[NCT01104649] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for riluzole and Autosomal Dominant Cerebellar Ataxia, Type II
| Article | Year |
|---|---|
Spinocerebellar ataxia.
Topics: Age Factors; Disease Progression; Humans; Mass Screening; Neuroprotective Agents; Postural Balance; | 2019 |
2 trials available for riluzole and Autosomal Dominant Cerebellar Ataxia, Type II
| Article | Year |
|---|---|
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Brain; Double-Blind Method; Female; Humans; Riluzole; Spinocerebellar Ataxias; Treatment Outc | 2022 |
Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Friedreich Ataxia; Humans; Ma | 2015 |
5 other studies available for riluzole and Autosomal Dominant Cerebellar Ataxia, Type II
| Article | Year |
|---|---|
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial.
Topics: Humans; Riluzole; Spinocerebellar Ataxias | 2022 |
Rare inherited diseases merit disease-specific trials.
Topics: Excitatory Amino Acid Antagonists; Female; Friedreich Ataxia; Humans; Male; Riluzole; Spinocerebella | 2015 |
Movement disorders: Repurposing riluzole to treat hereditary cerebellar ataxia.
Topics: Excitatory Amino Acid Antagonists; Female; Friedreich Ataxia; Humans; Male; Riluzole; Spinocerebella | 2015 |
Vulnerability of Purkinje Cells Generated from Spinocerebellar Ataxia Type 6 Patient-Derived iPSCs.
Topics: Calcium Channels, N-Type; Cell Differentiation; Humans; Induced Pluripotent Stem Cells; Protein Doma | 2016 |
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
Topics: Amantadine; Animals; Ataxin-1; Ataxins; Buspirone; Disease Models, Animal; Dopamine Agents; Genotype | 2013 |